Nobivac^® NXT FeLV: The Next Generation of Non-Adjuvanted Protection

About This Webinar

Feline leukemia virus (FeLV) is not a new thing. We have all been diagnosing and managing FeLV for as long as we have been in veterinary practice, and the attention we pay to this retrovirus is well-deserved. Infection with FeLV sets the stage for a battle between the cat’s immune system and the virus: with potential lifelong consequences. Safe and effective protection against this pathogen is of paramount importance, and Merck Animal Health’s Nobivac^® NXT FeLV brings that protection to the next level with cutting-edge vaccine technology in a non-adjuvanted, 0.5 mL dose with a two-year duration of immunity. In this presentation, Dr. Laura Greene, DVM, DACVIM (SAIM) will take us through how RNA particle vaccines are allowing us to protect our feline friends against an old virus in an entirely new way.